Last week, OSI Pharmaceuticals
Tarceva, which OSI co-promotes with Genentech
Meanwhile, back in November, OSI announced its plan to divest its eye-disease business, which consists primarily of a product that it has marketed with Pfizer
At for Tarceva, it has received positive results in a phase 3 study showing that adding the drug to chemotherapy can significantly improve survival in patients with pancreatic cancer. And aside from the strong growth and promising future for Tarceva, OSI has also done well for itself by keeping its expenses in check with slight decreases in cost of goods sold and sales, general, and administrative expenses.
Checking in with our Motley Fool CAPS community reveals that the sentiment on OSI is fairly divided. The stock has a one-star rating, out of a possible five, with bulls outnumbering the bears by a slim count. Among the bears, CAPS player pquery doesn't pull any punches with his take on the stock: "Take your gains while they're there with this one." Only time will tell which sentiment is correct, but in the meantime, shareholders should be feeling upbeat with the company's Q1 results.